Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives.
Summary withdrawn
TitrateLab removes an AI-written study summary when it states findings we cannot trace to the study's own record, or when the study falls outside the compounds we track. Read the original record through the link above.
tirzepatide
obesity
gut-microbiota
metabolic-syndrome
glp-1-agonist
gip-agonist